Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation

被引:5
作者
Brown, Michael [1 ,2 ]
Saund, Jasjot [1 ]
Qureshi, Azka [3 ,4 ]
Plowright, Megan [5 ,6 ]
Drury, Katie [7 ]
Gahir, Joshua [1 ]
Simpson, Tom [8 ]
Newman, Thomas [5 ,6 ]
Adams, Kate [7 ]
Galloway, James [9 ]
Durairaj, Kezia [3 ,4 ]
Elgizouli, Kamla [7 ]
Rampling, Tommy [1 ]
Cole, Joby [5 ,6 ]
Easom, Nicholas [7 ]
Goodman, Anna L. [3 ,4 ,10 ]
Marks, Michael [1 ,2 ,11 ]
机构
[1] Univ Coll London Hosp NHS Fdn Trust, Div Infect, London, England
[2] London Sch Hyg & Trop Med, Clin Res Dept, London, England
[3] Guys & St Thomass NHS Fdn Trust, Dept Infect, London, England
[4] Guys & St Thomass NHS Fdn Trust, South East London Covid Prevent & Intervent Serv, London, England
[5] Sheffield Teaching Hosp NHS Fdn Trust, Dept Infect Dis & Trop Med, Sheffield, S Yorkshire, England
[6] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England
[7] Hull Univ Teaching Hosp NHS Fdn Trust, Infect Res Grp, Kingston Upon Hull, N Humberside, England
[8] Lewisham Hosp, Dept Resp Med, London, England
[9] Kings Coll London, Ctr Rheumat Dis, London, England
[10] UCL, Clin Trials Unit, MRC, London, England
[11] UCL, Div Infect & Immun, London, England
来源
OPEN FORUM INFECTIOUS DISEASES | 2022年 / 9卷 / 10期
关键词
COVID-19; sotrovimab; molnupiravir;
D O I
10.1093/ofid/ofac527
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background COVID-19 medicines delivery units (CMDU) were established in late December 2021 to deliver early antiviral therapy to patients classified as at risk with the aim of preventing hospitalization. Methods We performed a service evaluation at 4 CMDUs in England. We assessed demographics and triage outcomes of CMDU referral, uptake of antiviral therapy, and the rate of subsequent hospitalizations within 2 weeks of CMDU referral. Results Over a 3-week period, 4788 patients were referred and 3989 were ultimately assessed by a CMDU. Overall, 832 of the patients referred (17%) were judged eligible for treatment and 628 (13%) were ultimately prescribed an antiviral agent. The overall rate of admission within 14 days was 1%. Patients who were admitted were significantly older than those who did not require hospitalization. Of patients prescribed molnupiravir and sotrovimab, 1.8% and 3.2%, respectively, were admitted. Conclusions There was a high volume of referrals to CMDU service during the initial surge of the Omicron wave in the United Kingdom. A minority of patients were judged to be eligible for therapy. In a highly vaccinated population, the overall hospitalization rate was low.
引用
收藏
页数:5
相关论文
共 17 条
  • [1] Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
    Bernal, A. Jayk
    da Silva, M. M. Gomes
    Musungaie, D. B.
    Kovalchuk, E.
    Gonzalez, A.
    Delos Reyes, V
    Martin-Quiros, A.
    Caraco, Y.
    Williams-Diaz, A.
    Brown, M. L.
    Du, J.
    Pedley, A.
    Assaid, C.
    Strizki, J.
    Grobler, J. A.
    Shamsuddin, H. H.
    Tipping, R.
    Wan, H.
    Paschke, A.
    Butterton, J. R.
    Johnson, M. G.
    De Anda, C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06) : 509 - 520
  • [2] Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
    Carr, Edward J.
    Wu, Mary
    Harvey, Ruth
    Billany, Roseanne E.
    Wall, Emma C.
    Kelly, Gavin
    Howell, Michael
    Kassiotis, George
    Swanton, Charles
    Gandhi, Sonia
    Bauer, David L. V.
    Graham-Brown, Matthew P. M.
    Jones, Rachel B.
    Smith, Rona M.
    McAdoo, Stephen
    Willicombe, Michelle
    Beale, Rupert
    [J]. LANCET, 2022, 399 (10327) : 800 - 802
  • [3] Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
    Cheng, Samuel M. S.
    Mok, Chris Ka Pun
    Leung, Yonna W. Y.
    Ng, Susanna S.
    Chan, Karl C. K.
    Ko, Fanny W.
    Chen, Chunke
    Yiu, Karen
    Lam, Bosco H. S.
    Lau, Eric H. Y.
    Chan, Ken K. P.
    Luk, Leo L. H.
    Li, John K. C.
    Tsang, Leo C. H.
    Poon, Leo L. M.
    Hui, David S. C.
    Peiris, Malik
    [J]. NATURE MEDICINE, 2022, 28 (03) : 486 - +
  • [4] Curtis HJ, 2022, BRIT J GEN PRACT, V72, pE51, DOI 10.3399/BJGP.2021.0376
  • [5] Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
    Docherty, Annemarie B.
    Harrison, Ewen M.
    Green, Christopher A.
    Hardwick, Hayley E.
    Pius, Riinu
    Norman, Lisa
    Holden, Karl A.
    Read, Jonathan M.
    Dondelinger, Frank
    Carson, Gail
    Merson, Laura
    Lee, James
    Plotkin, Daniel
    Sigfrid, Louise
    Halpin, Sophie
    Jackson, Clare
    Gamble, Carrol
    Horby, Peter W.
    Nguyen-Van-Tam, Jonathan S.
    Ho, Antonia
    Russell, Clark D.
    Dunning, Jake
    Openshaw, Peter Jm
    Baillie, J. Kenneth
    Semple, Malcolm G.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [6] Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
    Gottlieb, R. L.
    Vaca, C. E.
    Paredes, R.
    Mera, J.
    Webb, B. J.
    Perez, G.
    Oguchi, G.
    Ryan, P.
    Nielsen, B. U.
    Brown, M.
    Hidalgo, A.
    Sachdeva, Y.
    Mittal, S.
    Osiyemi, O.
    Skarbinski, J.
    Juneja, K.
    Hyland, R. H.
    Osinusi, A.
    Chen, S.
    Camus, G.
    Abdelghany, M.
    Davies, S.
    Behenna-Renton, N.
    Duff, F.
    Marty, F. M.
    Katz, M. J.
    Ginde, A. A.
    Brown, S. M.
    Schiffer, J. T.
    Hill, J. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) : 305 - 315
  • [7] Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
    Gupta, Anil
    Gonzalez-Rojas, Yaneicy
    Juarez, Erick
    Casal, Manuel Crespo
    Moya, Jaynier
    Falci, Diego R.
    Sarkis, Elias
    Solis, Joel
    Zheng, Hanzhe
    Scott, Nicola
    Cathcart, Andrea L.
    Hebner, Christy M.
    Sager, Jennifer
    Mogalian, Erik
    Tipple, Craig
    Peppercorn, Amanda
    Alexander, Elizabeth
    Pang, Phillip S.
    Free, Almena
    Brinson, Cynthia
    Aldinger, Melissa
    Shapiro, Adrienne E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21) : 1941 - 1950
  • [8] Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies
    Herrera-Esposito, Daniel
    de los Campos, Gustavo
    [J]. BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [9] Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
    Menni, Cristina
    Valdes, Ana M.
    Polidori, Lorenzo
    Antonelli, Michela
    Penamakuri, Satya
    Nogal, Ana
    Louca, Panayiotis
    May, Anna
    Figueiredo, Jane C.
    Hu, Christina
    Molteni, Erika
    Canas, Liane
    Osterdahl, Marc F.
    Modat, Marc
    Sudre, Carole H.
    Fox, Ben
    Hammers, Alexander
    Wolf, Jonathan
    Capdevila, Joan
    Chan, Andrew T.
    David, Sean P.
    Steves, Claire J.
    Ourselin, Sebastien
    Spector, Tim D.
    [J]. LANCET, 2022, 399 (10335) : 1618 - 1624
  • [10] National Health Service, COR INT CLIN COMM PO